Literature DB >> 17910634

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.

Babatunde O Oyajobi1, I Ross Garrett, Anjana Gupta, Alda Flores, Javier Esparza, Steve Muñoz, Ming Zhao, Gregory R Mundy.   

Abstract

Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mouse calvarial cultures; this effect was blocked by dickkopf 1(Dkk1), an antagonist of Wnt signalling implicated in myeloma bone disease. Bortezomib inhibited Dkk1 expression in calvariae and bone marrow-derived stromal cells, suggesting a novel mechanism by which bortezomib exerts its effects in bone. Clinical trials in patients with myeloma bone disease are needed to validate these results.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17910634      PMCID： PMC4482356          DOI： 10.1111/j.1365-2141.2007.06829.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  14 in total

1.  Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

Authors:  I R Garrett; D Chen; G Gutierrez; M Zhao; A Escobedo; G Rossini; S E Harris; W Gallwitz; K B Kim; S Hu; C M Crews; G R Mundy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  Assessing bone formation using mouse calvarial organ cultures.

Authors:  I Ross Garrett
Journal:  Methods Mol Med       Date:  2003

3.  Biologic and therapeutic determinants of bone mineral density in multiple myeloma.

Authors:  M V Dhodapkar; R Weinstein; G Tricot; S Jagannath; A M Parfitt; S C Manolagas; B Barlogie
Journal:  Leuk Lymphoma       Date:  1998-12

4.  The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.

Authors:  José Manuel González-Sancho; Oscar Aguilera; José Miguel García; Natalia Pendás-Franco; Cristina Peña; Santiago Cal; Antonio García de Herreros; Félix Bonilla; Alberto Muñoz
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

5.  Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

Authors:  Maurizio Zangari; Dixie Esseltine; Choon-Kee Lee; Bart Barlogie; Francesca Elice; Michael J Burns; Seung-Hee Kang; Shmuel Yaccoby; Kevin Najarian; Paul Richardson; Peter Sonneveld; Guido Tricot
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

6.  Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

Authors:  Evangelos Terpos; Deborah J Heath; Amin Rahemtulla; Kostas Zervas; Andrew Chantry; Athanasios Anagnostopoulos; Anastasia Pouli; Eirini Katodritou; Evgenia Verrou; Elisavet-Christine Vervessou; Meletios-Athanassios Dimopoulos; Peter I Croucher
Journal:  Br J Haematol       Date:  2006-12       Impact factor: 6.998

Review 7.  Bortezomib: proteasome inhibition as an effective anticancer therapy.

Authors:  Paul G Richardson; Constantine Mitsiades; Teru Hideshima; Kenneth C Anderson
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

8.  A role for Wnt/beta-catenin signaling in lens epithelial differentiation.

Authors:  Richard J W Stump; Sharyn Ang; Yongjuan Chen; Tatiana von Bahr; Frank J Lovicu; Kathleen Pinson; Robbert U de Iongh; Terry P Yamaguchi; David A Sassoon; John W McAvoy
Journal:  Dev Biol       Date:  2003-07-01       Impact factor: 3.582

9.  Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases.

Authors:  W Withold; U Schulte; H Reinauer
Journal:  Clin Chem       Date:  1996-02       Impact factor: 8.327

10.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245
View more
  36 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 3.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 4.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 5.  Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.

Authors:  Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

6.  Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Authors:  Claire M Edwards; Seint T Lwin; Jessica A Fowler; Babatunde O Oyajobi; Junling Zhuang; Andreia L Bates; Gregory R Mundy
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

7.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Maurizio Zangari; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047

9.  A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.

Authors:  Bruce P Ayati; Claire M Edwards; Glenn F Webb; John P Wikswo
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

10.  First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Authors:  Thomas Lund; Kent Søe; Niels Abildgaard; Patrick Garnero; Per T Pedersen; Tina Ormstrup; Jean-Marie Delaissé; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-07-22       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.